Michael E. Kamarck's most recent trade in Vaxcyte Inc was a trade of 15,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 13, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Vaxcyte Inc | Michael E. Kamarck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
Vaxcyte Inc | Michael E. Kamarck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 2,500 | 5,625 | - | 0 | Common Stock | |
Passage Bio Inc | Michael E. Kamarck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 21,567 | 21,567 | - | - | Director Stock Option (Right to Buy) | |
Passage Bio Inc | Michael E. Kamarck | Director | 05 Jul 2022 | 48,000 | 48,000 | - | - | Stock Option (right to buy) | ||
Vaxcyte Inc | Michael E. Kamarck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 18,750 | 18,750 | - | - | Stock Option (right to buy) | |
Vaxcyte Inc | Michael E. Kamarck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 3,125 | 3,125 | - | 0 | Common Stock | |
Vaxcyte Inc | Michael E. Kamarck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |